ORKA Stock Analysis: Buy, Sell, or Hold?
ORKA - Oruka Therapeutics, Inc. Common Stock
$34.23
-1.03 (-2.92%)
▼
5d:
-0.47%
30d:
+17.55%
90d:
+23.98%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 05, 2026
30d
Get Alerted When ORKA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ORKA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ORKA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ORKA is currently trading at $34.23, which is considered slightly high relative to its 30-day fair value range of $28.58 to $34.51.
Technical Outlook: Technically, ORKA is in a strong uptrend. Immediate support is located at $31.61, while resistance sits at $36.51.
Market Sentiment: ORKA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $55.67 (+62.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORKA is in a strong uptrend. Immediate support is located at $31.61, while resistance sits at $36.51.
Market Sentiment: ORKA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $55.67 (+62.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$28.58 -
$34.51
Company Quality Score
63/100
(BUY)
Options IV Signal
11th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Options cheap (IV 11th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.6% below Wall St target ($55.67)
Fair Price Analysis
30-Day Fair Range
$28.58 -
$34.51
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$5.24
(15.3%)
Support & Resistance Levels
Support Level
$31.61
Resistance Level
$36.51
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-14.32
Wall Street Target
$55.67
(+62.6%)
Last updated: February 02, 2026 7:58 AM ET
Data refreshes hourly during market hours. Next update: 8:58 AM
Data refreshes hourly during market hours. Next update: 8:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORKA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$514 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 60 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$847 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$89 | 61 BUY |
